Antibodies responding to covid-19 coronavirus, illustration

Regeneron’s COVID-19 Antibody “Cocktail” Granted Emergency Use Authorization by FDA

Before patients can be treated with REGEN-COV2 under the EUA, they must weigh at least 40 kilograms (about 88 pounds) and be deemed at high risk for progressing to severe COVID-19 and/or hospitalization. That high-risk category includes adults who are ages 65 or older, or who have chronic medical conditions.


Neuron system

Researchers ID 40 Genes that Thwart Axon Regeneration in CNS Cells

When the researchers suppressed those genes in mouse models of glaucoma they were able to regenerate the damaged axons. The findings could eventually lead to developing therapies for patients of stroke, spinal cord damage, or traumatic brain injuries—avenues that don't currently exists.

FDA Approves Myriad BRACAnalysis CDx for Lynparza in Metastatic Pancreatic Cancer

According to Myriad, it is the first and only genetic test approved by the FDA as a CDx designed to help identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with Lynparza.
elderly man with head breaking apart

Feasibility Study Finds Informative Digital Biomarkers of Dementia

Combining wearable devices, handheld devices and digital apps lets researchers tell the difference between people with early dementia and those without it.

Are Biomarkers in Semen the Future of Prostate Cancer Screening?

Semen could be considered a liquid biopsy of the organs of male reproductive system—specifically, of the prostate gland. This is convenient. Semen is, potentially,...

Promega to Develop MSI Technology as CDx to Merck’s Keytruda

Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.
remdesivir covid-19 liquid medication background

COVID-19 Antiviral Treatment Remdesivir’s Effectiveness Boosted 10X by Hepatitis C Drug

The study's authors suggested their work could lead to a combination antiviral therapy for COVID-19, which could be especially helpful to unvaccinated people who become infected and to vaccinated people who experience waning immunity.
Source: Christoph Bock/Max Planck Institute for Informatics

Cancer Prognosis and Survival Predictions Aided by DNA Methylation Patterns

DNA methylation could improve outcomes via more accurate diagnoses of indolent or aggressive tumors requiring different treatment regimens
University of Oxford and AstraZeneca vaccine

AstraZeneca/Oxford COVID-19 Vaccine Shows 76% Efficacy, Reduced Transmission

The vaccine also showed potential for reducing transmission of the virus, with researchers finding a 67% reduction in positive swabs obtained from volunteers in the U.K. arms of the trials following the first dose.
Qiagen plans to acquire diagnostics developer STAT-Dx for up to $191 million

Qiagen to Acquire Diagnostics Developer STAT-Dx for $147M, Plus Milestones

Later this year, combined company plans to launch QIAstat-Dx, designed for use in oncology and respiratory or gastrointestinal infections
Faecali bacterium

Prime Time for the Microbiome

With some positive results in the clinic, there are other encouraging signs the field is maturing and branching into other therapeutic areas such as oncology.

RNA for Medical Analysis

From Mendelian disorders to COVID-19, academic and industrial scientists use these nucleic acids to help diagnose diseases.
woman in lab

Top Women in Precision Medicine

In our second installment of women making their mark in the field, Clinical OMICs interviews Bonnie Anderson of Veracyte, Tina Hambuch of Invitae, and Cindy Perettie of Foundation Medicine.
Jeanne Carroll, MD with baby

Saving Baby Nathan

California Medicaid’s pilot program Project Baby Bear delivers better outcomes at lower cost via rapid whole-genome sequencing of critically ill newborns.

Payer Policies not Sole Reason for Inconsistent Utilization of Genomic Testing

A report from the Personalized Medicine Coalition found significant variability in the use of genomic testing for patients not only from state to state, but also within states.
Scroll Up